fashion -WSS

fashion

author：Wikipedia 2025-10-02 22:58:15 - browse：16434

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

entertainment

explore

WSS

Bird flu outbreak in cows is latest avian flu curveball

Prescription digital therapeutics are key to pharma’s future

AstraZeneca lung cancer study comes in below expectations

Exact Sciences stock tumbles despite strong cancer detection sales

Fatty liver disease was alleviated by Lilly’s ‘triple

UnitedHealth financials solid despite Change Healthcare cyberattack

explore

fashion

leisure time

Virginia high school admissions case could be legal follow

Cell therapy fails to slow type 1 diabetes, but safety is established

How to save PrEP access — and even expand it

The wait for US passports is creating travel purgatory and snarling summer plans

Heart attack and stroke risk calculators need revising

Canadians with cystic fibrosis outlive Americans by a decade

Medical records are filled with copy

Diversity in clinical trials starts with building trust, experts say

Apple is now the first public company to be valued at $3 trillion

How Robert F. Kennedy Jr. distorted vaccine science

focus

Getting Alzheimer's drug Leqembi to patients can be a challenge

After traumatic brain injury, life support decisions can use more time

Orangutan used medicinal plant to treat wound, first time ever seen

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

'Screen and refer' systems are hurting patients

Undocumented workers face uncertainty as immigration law takes effect in Florida

entertainment

explore

hotspot

focus